Forest Laboratories Enters Collaboration on Bystolic(R) and Savella(R) in Canada
NEW YORK, Nov 11, 2010 (BUSINESS WIRE) -- Forest Laboratories, Inc. (Forest) (NYSE: FRX) today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic(R) (nebivolol) and Savella(R) (milnacipran HCl) in Canada with Janssen
Harvard Program on Negotiation, March 28-30, 2011 Cambridage Massacheusetts. Excellent program by top ranked thinkers on negotiation.
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
